Abstract
Traditional neoadjuvant therapy for esophageal cancer has used chemoradiation doses greater than 45Gy. This study aimed to examine the dose of preoperative radiation in relation to the pathologic complete response (pCR) rate and overall survival (OS) for patients with resectable esophageal cancer. The National Cancer Database was queried for all patients with esophageal or gastroesophageal junction cancer who received neoadjuvant chemoradiation (CRT) followed by esophagectomy between 2006 and 2015. The radiation doses were divided into four rangesbased on Grays (Gy)received: less than 39.6Gy, 39.60-44.99Gy, 45-49.99Gy, and 50Gy or more. The inclusion criteria were met by 10,293 patients. All patients received neoadjuvant CRT, with 689 patients (6.7%) receiving less than 39.6Gy, 973 patients (9.5%) receiving 39.6-44.9Gy, 3837 patients (37.3%) receiving 45-49.9Gy, and 4794 patients (46.6%) receiving 50Gy or more. The overall pCR rate was 17.2% (1769/10,293) and was significantly lower for those who received less than 39.6Gy of radiation than for those who received 39.6Gy or more (13.9% [96/689] vs. 17.4% [1673/9604]; p = 0.017). The median OS of 37.2months was significantly better for those who received 39.6Gy or more than for those who received less than 39.6Gy (38 vs. 29.6months (p < 0.0001). The pCR and OS did not differ between the three higher radiation doses (39.6-44.9 vs. 45-49.9Gy vs. ≥ 50Gy; pCR [p = 0.1] vs. OS [p = 0.097]). The patients who received 39.6-44.9Gy were propensity matched with those who received 45Gy or more of radiation. There remained no difference in pCR (p = 0.375) or OS (p = 0.957). In the United States, the heterogeneity in neoadjuvant CRT dosing is significant, with 84% of patients receiving more than 45Gy. The benefit of neoadjuvant CRT in terms of pCR and overall survival is seen with doses of 39.6Gy or more, but not with doses higher than 45Gy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
